uniQure (NASDAQ:QURE) Stock Rating Reaffirmed by HC Wainwright

uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $25.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 393.10% from the company’s […]

Leave a Reply

Your email address will not be published.

Previous post McKesson (NYSE:MCK) PT Raised to $596.00
Next post Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00